Compare Analog Devices, Inc. (ADI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Analog Devices, Inc. trades at $384.56 (market cap $187.67B), while State Street SPDR S&P Biotech ETF trades at $159.03. The key difference: Analog Devices, Inc. pays a 1.14% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Analog Devices, Inc. nearer its low. Which is the better fit depends on your goals.
| ADI | XBI | |
|---|---|---|
Market Cap | $187.67B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $445.48 | $164.28 |
52-Week Low | $225.20 | $86.92 |
Enterprise Value | $192.92B | — |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.29, up 0.1% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q1 2026 EPS of $3.09, exceeding expectations, and maintains strong profitability with a 26.01% net income margin. A dividend of $1.10 per share is scheduled for payment on June 16, 2026, reflecting cash flow stability.
ADI presents a favorable investment case with analyst consensus strongly bullish (79.63% buy ratings) and a price target of $472.29, implying significant upside. Risks include elevated valuation multiples (P/E of 57.34) and semiconductor cycle volatility, but robust fundamentals and AI-driven demand support long-term growth prospects.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
